KPTIThe 0.89 level seems to function as support and could be a good basis to head towards the upper resistances, 1.17-1.40, 1.6 otherwise the collapse of this level towards new lows
25K trade ideas
KPTIthe support in area 092 holds and from here it seems to bounce towards the resistance in area 1.2 and then 1.4; otherwise the failure of the 092 area support would lead to a bearish scenario
$KPTI: Low risk buy signalNice setup in $KPTI, I suggest buying these names with small positions considering the volatility that can occur after catalysts when new data is released, or around FDA approvals, etc.
Upside can be substantial though, so if technicals and fundamentals align, it's worth keeping some exposure.
Best of luck!
Cheers,
Ivan Labrie.
KPTI - Falling WedgeFalling wedge idea for KPTI.
Areas above the arrows up are very similar hence I propose a breakout of the falling wedge is coming.
Falling wedges are considered a bullish pattern.
Bearish Bearish Divergence on the 1 hr chart. I am selling short here. Quick trade, as it is the 1 hr after all.
KPTI | LongNASDAQ:KPTI
Possible Scenario: Long
Evidence: Price Action, IH&S, Money-Flow
TP1: 7.85$
Call options, 01/21/2022, Strike 7.5$
*This is my idea and could be wrong 100%
$KPTI Target PTs 18-29 and higherAntengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma
SHANGHAI and HONG KONG, April 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, today announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for a Phase I clinical trial to evaluate safety and tolerability of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL) in China.
As an orally bioavailable dual PAK4/NAMPT inhibitor, ATG-019 can lead to antitumor effects through energy depletion, inhibition of DNA repair, cell cycle arrest, inhibition of proliferation, and ultimately cell apoptosis. Hematological and solid tumor cells that are dependent on both PAK4 and NAMPT pathways may be susceptible to single-agent anti-tumor activity by ATG-019. ATG-019 has clear preclinical anti-tumor activity and a superior pharmacokinetics (PK) and safety profile making it an attractive novel drug candidate. Antengene has recently been conducting a Phase I clinical trial (TEACH) of ATG-019 in advanced solid tumors and NHL in Taiwan.
"The NMPA's approval of the IND application for ATG-019 indicates the potential of this drug to be applied to Chinese patients. We look forward to initiating the first clinical trial of ATG-019 in mainland China," said Dr. Jay Mei, Founder, Chairman and CEO of Antengene. "ATG-019 is an orally available dual PAK4/NAMPT inhibitor that achieves synergistic antitumor effects through the co-inhibition of the two pathways. We believe that ATG-019, as a novel agent under investigation, can potentially provide an additional treatment option for patients with advanced solid tumor and NHL."
About ATG-019
ATG-019 is a global first-in-class oral dual PAK4/NAMPT inhibitor developed by Karyopharm Therapeutics Inc. (NASDAQ: KPTI). Antengene reached an exclusive agreement of cooperation and authorization with Karyopharm and obtained the exclusive development and commercialization rights of ATG-019 in multiple Asia-Pacific markets, including Greater China, South Korea, Australia, New Zealand and ASEAN countries.
PAK4 is a signaling protein regulating numerous fundamental cellular processes, including intracellular transport, cellular division, cell shape and motility, cell survival, immune defense and the development of cancer. PAK4 interacts with many key signaling molecules involved in cancer development such as beta-catenin, CDC42, Raf-1, BAD and myosin light chain. NAMPT is a pleiotropic protein with intra- and extra-cellular functions as an enzyme, cytokine, growth factor, and hormone that can be found in a complex with PAK4 in the cell. In preclinical mouse models, ATG-019 in combination with anti-PD-1 therapies showed improved antitumor efficacy over anti-PD-1 monotherapy, indicating the potential of the combined therapy to treat anti-PD-1 resistant patients.
Antengene is conducting a Phase I clinical trial of ATG-019 in Taiwan in patients with advanced NHL and solid tumors and are planning to conduct clinical trials exploring its combination potential with other agents.
About Antengene
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the Asia Pacific Region, and around the world. Since its establishment, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets and obtained 13 investigational new drug approvals in Asia Pacific. The vision of Antengene is to "Treat Patients Beyond Borders". Antengene aims to address significant unmet medical needs by discovering, developing, and commercializing first-in-class/best-in-class therapeutics.
$KPTI 4hr MACD/RSI HBD Daily MACD HBD at supportThis one was brought to my attention by California Hip Hop Rap Underrated during ChampionVibe's Livestream a few days ago. I see this withing a channel while maybe looking left it could also look like a ascending broadening wedge which should be taken into account. Risk management is easy here and there is an edge for the bulls on the osciliators so I will play this in the short term for a 3 R/R. Marked on chart. If the momentum continues it could test the 200MA and if it breaks the 200ma I would target the top of the channel.
Bullish Cup and handle formation in KPTIThe chart is consolidating in range of 14 after having made a huge cup and coning out of handle pattern, may start uprun towards 20, SL:13.75. Once the cup and handle pattern give successful breakout near 20, may cross 30.
Disclaimer: The stock/index/currency discussed do not constitute Investment/trading advise and is merely an effort towards enhancing learning, knowledge and book keeping. Kindly do your own due diligence and/or consult investment advisor before making any investment/trading decisions
Easy swingKPTI has been trading in a range with Earnings expected on Feb. 11. Experts expect KPTI to grow exponentially over next few years. At worst, swing this from 15 - 17.5. At best, buy at 15 and hold until breakout.
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a TrKPTI: Karyopharm Therapeutics Inc.
2020-12-18 11:30:00
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
KPTI Looking Ready to Break OutForming a penant. Broke out of its diagonal R/S line, now going up against the main trend diagonal. RSI looking healthy, trend is its favor.
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for theKPTI: Karyopharm Therapeutics Inc.
2020-06-22 11:25:10
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
watch for support and resistance lineswatch for price/volume actions at these prices on support and resistance lines and jump in or out based on that.
BUY It has lost in value, so a correction is due. The volume and breakout support this idea. SL at 4.3$ area, first target 7.6
(Nasdaq: KPTI) Karyopharm tx "catching a falling knife"Recently FDA released data suggesting KPTI and myloma medicationi was too "Toxic" their MM chemo drug had SERIOUS toxicity AEs and even DEATH. Cohort of 123 pts ~86% had some sort of serious AE and ~24% dropped out because of this. to find out more about what happened and why SP dropped, see synopsis in the link below.
Synopsis of Data can be found here- opening bell 2/25/2018:
msmoneymoves.com
NDA application: -// Failed*
www.fda.gov
